TY - CHAP M1 - Book, Section TI - Chapter 48. The German Experience: Primary Systemic Therapy with Cytotoxic Agents A1 - Untch, Michael A1 - Minckwitz, Gunter von A2 - Kuerer, Henry M. PY - 2010 T2 - Kuerer's Breast Surgical Oncology AB - The success of preoperative, neoadjuvant chemotherapy for locally advanced and inflammatory breast cancer, combined with emerging data on the use of adjuvant chemotherapy, led to the evaluation of the primary systemic therapy (PST) (neoadjuvant) approach for women with primary operable breast cancer. Potential advantages of PST include increasing rates of breast conservation, reducing mortality with lower toxicity, and in vivo testing of sensitivity of cancer cells to the systemic therapy used.1 SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/10/03 UR - accesssurgery.mhmedical.com/content.aspx?aid=6413437 ER -